A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This Phase II study is open to patients with metastatic colorectal cancer who have tried but
failed chemotherapy regimens containing oxaliplatin and irinotecan. Patients must not have
received anti-EGFR (Epidermal Growth Factor Receptor) treatment (for example, cetuximab,
panitumumab) in the past. Patients with wild-type KRAS (v-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog) colorectal cancer will be randomised to receive either BIBW 2992 or
cetuximab. Patients with KRAS mutated colorectal cancer will not be randomised, but will all
receive BIBW 2992. The main objectives of the study are: to compare the effectiveness of BIBW
2992 with that of cetuximab in patients with KRAS wild type cancer, and to assess the
effectiveness of BIBW 2992 in patients with KRAS mutated cancer.